Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Leiomyosarcoma 2Ovarian Neoplasms 1Neoplasms 1Glioma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Doxorubicin 25Gemcitabine 16Trabectedin 12Ifosfamide 12Radiotherapy 11Docetaxel 10Dacarbazine 8pazopanib 7Nivolumab 6Specimen Handling 5Biopsy 5liposomal doxorubicin 4Temozolomide 4pembrolizumab 3Sunitinib 3Sorafenib 3Radiation 3Magnetic Resonance Spectroscopy 3Filgrastim 3rucaparib 2pegfilgrastim 2olaratumab 2eribulin 2durvalumab 2cixutumumab 2cemiplimab 2brostallicin 2belinostat 2avelumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leiomyosarcoma × PTC596 × Clear all
NCT05269355 2025-06-13

SUNRISELMS

PTC Therapeutics

Phase 2/3 Terminated
359 enrolled 15 charts
Sarcoma

Leiomyosarcoma

NCT03761095 2024-03-15

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

PTC Therapeutics

Phase 1 Completed
41 enrolled
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡